WO2004015069A2 - Mp2153 comme genes modificateurs de la voie de p21 ou de p53 et procedes d'utilisation - Google Patents

Mp2153 comme genes modificateurs de la voie de p21 ou de p53 et procedes d'utilisation Download PDF

Info

Publication number
WO2004015069A2
WO2004015069A2 PCT/US2003/024505 US0324505W WO2004015069A2 WO 2004015069 A2 WO2004015069 A2 WO 2004015069A2 US 0324505 W US0324505 W US 0324505W WO 2004015069 A2 WO2004015069 A2 WO 2004015069A2
Authority
WO
WIPO (PCT)
Prior art keywords
assay
agent
cell
candidate
pathway
Prior art date
Application number
PCT/US2003/024505
Other languages
English (en)
Other versions
WO2004015069A3 (fr
Inventor
Helen Francis-Lang
Lori Friedman
Thomas Kidd
Siobhan Roche
Marcia Belvin
Gregory D. Plowman
Kim Lickteig
Haiguang Zhang
Craig D. Amundsen
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Priority to AU2003263993A priority Critical patent/AU2003263993A1/en
Publication of WO2004015069A2 publication Critical patent/WO2004015069A2/fr
Publication of WO2004015069A3 publication Critical patent/WO2004015069A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1

Definitions

  • the p53 gene is mutated in over 50 different types of human cancers, including familial and spontaneous cancers, and is believed to be the most commonly mutated gene in human cancer (Zambetti and Levine, FASEB (1993) 7:855-865; Hollstein, et al, Nucleic Acids Res. (1994) 22:3551-3555). Greater than 90% of mutations in the ⁇ 53 gene are missense mutations that alter a single amino acid that inactivates p53 function.
  • the human p53 protein normally functions as a central integrator of signals including DNA damage, hypoxia, nucleotide deprivation, and oncogene activation (Prives, Cell (1998) 95:5-8). In response to these signals, p53 protein levels are greatly increased with the result that the accumulated p53 activates cell cycle arrest or apoptosis depending on the nature and strength of these signals. Indeed, multiple lines of experimental evidence have pointed to a key role for p53 as a tumor suppressor (Levine, Cell (1997) 88:323-331). For example, homozygous p53 "knockout" mice are developmentally normal but exhibit nearly 100% incidence of neoplasia in the first year of life (Donehower et al, Nature (1992) 356:215-221).
  • p53 function is its activity as a gene-specific transcriptional activator.
  • genes with known p53-response elements are several with well-characterized roles in either regulation of the cell cycle or apoptosis, including GADD45, p21/Wafl/Cipl, cyclin G, Bax, IGF-BP3, and DM2 (Levine, Cell (1997) 88:323-331).
  • the p21/CDKNl/WAFl/CIPl protein (El-Deiry, W. S.; et al. Cell 75: 817-825, 1993; Harper, J. W.; et al. Cell 75: 805-816, 1993; Huppi, Ket al. Oncogene 9: 3017-3020, 1994) is a cell cycle control protein that inhibits cyclin-kinase activity, is tightly regulated at the transcriptional level by p53, and mediates p53 suppression of tumor cell growth. Along with p53, p21 appears to be essential for maintaining the G2 checkpoint in human cells (Bunz, F.; Dutriaux, A.; et al. Science 282:1497-1501, 1998).
  • Sequences of P21 are well-conserved throughout evolution, and have been identified in species as diverse as human (Genbank Identifier 13643057), Drosophila melanogaster (GI# 1684911), Caenorhabditis elegans (GI#4966283), and yeast (GI#2656016).
  • model organisms such as Drosophila
  • Drosophila The ability to manipulate the genomes of model organisms such as Drosophila provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33- 74; Watson KL., et al., 1994 J Cell Sci.
  • a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner.
  • the gene When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point.
  • the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as p21 or p53, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.
  • MP2153 modifer of p21 and p53
  • the invention provides methods for utilizing these p21 or p53 modifier genes and polypeptides to identify MP2153-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired p21 or p53 function and/or MP2153 function.
  • MP2153-modulating agents specifically bind to MP2153 polypeptides and restore p21 or p53 function.
  • MP2153-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MP2153 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).
  • nucleic acid modulators such as antisense oligomers and RNAi that repress MP2153 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).
  • MP2153 modulating agents may be evaluated by any convenient in vitro or in vivo assay for molecular interaction with an MP2153 polypeptide or nucleic acid.
  • candidate MP2153 modulating agents are tested with an assay system comprising a MP2153 polypeptide or nucleic acid.
  • Agents that produce a change in the activity of the assay system relative to controls are identified as candidate p21 or p53 modulating agents.
  • the assay system may be cell-based or cell-free.
  • MP2153-modulating agents include MP2153 related proteins (e.g.
  • a small molecule modulator is identified using a binding assay.
  • the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.
  • candidate p21 or p53 pathway modulating agents are further tested using a second assay system that detects changes in the p21 or p53 pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent.
  • the second assay system may use cultured cells or non-human animals.
  • the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the p21 or p53 pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).
  • the invention further provides methods for modulating the MP2153 function and or the p21 or p53 pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a MP2153 polypeptide or nucleic acid.
  • the agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the p21 or p53 pathway.
  • Drosophila Drosophila.
  • p53 a genetic modifier screen was carried out in which p53 was overexpressed in the wing (Ollmann M, et al, Cell 2000 101: 91-101).
  • p21 a dominant loss of function screen was carried out in Drosophila to identify genes that interact with the cyclin dependent kinase inhibitor, p21 (Bourne HR, et al., Nature (1990) 348(6297): 125-132; Marshall CJ, Trends Genet (1991) 7(3):91-95). Expression of the p21 gene in the eye causes deterioration of normal eye morphology. Modifiers of the eye phenotype were identified as members of the p21 pathway.
  • modifiers were identified, followed by identification of their orthologs. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MP2153 genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective p21 or p53 signaling pathway, such as cancer.
  • Table 1 Example JJI lists the modifiers and their orthologs.
  • MP2153 modulating agents that act by inhibiting or enhancing MP2153 expression, directly or indirectly, for example, by affecting an MP2153 function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein.
  • MP2153 modulating agents are useful in diagnosis, therapy and pharmaceutical development.
  • MP2153 polypeptide refers to a full-length MP2153 protein or a functionally active fragment or derivative thereof.
  • a "functionally active" MP2153 fragment or derivative exhibits one or more functional activities associated with a full- length, wild-type MP2153 protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc.
  • the functional activity of MP2153 proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan et al, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below.
  • a functionally active MP2153 polypeptide is a MP2153 derivative capable of rescuing defective endogenous MP2153 activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species.
  • functionally active fragments also include those fragments that comprise one or more structural domains of an MP2153, such as a kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods for obtaining MP2153 polypeptides are also further described below.
  • preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of an MP2153. In further preferred embodiments, the fragment comprises the entire functionally active domain.
  • MP2153 nucleic acid refers to a DNA or RNA molecule that encodes a MP2153 polypeptide.
  • the MP2153 polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MP2153.
  • Methods of identifying orthlogs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3- dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences.
  • a single gene in one species may correspond to multiple genes (paralogs) in another, such as human.
  • paralogs encompasses paralogs.
  • percent (%) sequence identity with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0al9 (Altschul et al, J. Mol. Biol.
  • HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched.
  • a % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.
  • Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.
  • an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas et al., 1998, "A tutorial on Searching Sequence Databases and Sequence Scoring Methods” (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650).
  • This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl.
  • Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of an MP2153.
  • the stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g., Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook et al, Molecular Cloning, Cold Spring Harbor (1989)).
  • a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of an MP2153 under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (IX SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 ⁇ g/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, IX Denhardt's solution, 100 ⁇ g ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for lh in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).
  • SSC single strength citrate
  • moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.
  • low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.
  • MP2153 nucleic acids and polypeptides are useful for identifying and testing agents that modulate MP2153 function and for other applications related to the involvement of MP2153 in the p21 or p53 pathway.
  • MP2153 nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art.
  • PCR polymerase chain reaction
  • the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes.
  • Proteins to be purified for screening or antibody production may require the addition of specific tags (e.g., generation of fusion proteins).
  • Overexpression of an MP2153 protein for assays used to assess MP2153 function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities.
  • recombinant MP2153 is expressed in a cell line known to have defective p21 or p53 function (e.g. SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29 and DLD-1 colon cancer cells, among others, for p53 and HCT116 colon cancer cells for p21,available from American Type Culture Collection (ATCC), Manassas, NA).
  • the recombinant cells are used in cell-based screening assay systems of the invention, as described further below.
  • the nucleotide sequence encoding an MP2153 polypeptide can be inserted into any appropriate expression vector.
  • the necessary transcriptional and translational signals can derive from the native MP2153 gene and/or its flanking regions or can be heterologous.
  • a variety of host- vector expression systems may be utilized, such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA.
  • virus e.g. vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g. baculovirus
  • microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA.
  • An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.
  • the expression vector can comprise a promoter operably linked to an MP2153 gene nucleic acid, one or more origins of replication, and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, etc.).
  • selectable markers e.g. thymidine kinase activity, resistance to antibiotics, etc.
  • recombinant expression vectors can be identified by assaying for the expression of the MP2153 gene product based on the physical or functional properties of the MP2153 protein in in vitro assay systems (e.g. immunoassays).
  • the MP2153 protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection.
  • a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product.
  • a chimeric product may also be made by protein synthetic techniques, e.g. by use of a peptide synthesizer (Hunkapiller et al, Nature (1984) 310:105-111).
  • the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis).
  • native MP2153 proteins can be purified from natural sources, by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.
  • the methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MP2153 or other genes associated with the p21 or p53 pathway.
  • mis-expression encompasses ectopic expression, over- expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).
  • Animal models that have been genetically modified to alter MP2153 expression may be used in in vivo assays to test for activity of a candidate p21 or p53 modulating agent, or to further assess the role of MP2153 in a p21 or p53 pathway process such as apoptosis or cell proliferation.
  • the altered MP2153 expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MP2153 expression.
  • the genetically modified animal may additionally have altered p21 or p53 expression (e.g. p21 or p53 knockout).
  • Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others.
  • Preferred non-mammalian species include zebrafish, C. elegans, and Drosophila.
  • Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761- 763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells).
  • Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.
  • transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat.
  • Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. et al. (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).
  • the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous MP2153 gene that results in a decrease of MP2153 function, preferably such that MP2153 expression is undetectable or insignificant.
  • Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it.
  • the transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species.
  • a mouse MP2153 gene is used to construct a homologous recombination vector suitable for altering an endogenous MP2153 gene in the mouse genome.
  • homologous recombination vector suitable for altering an endogenous MP2153 gene in the mouse genome.
  • Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner et al, Nature (1989) 338: 153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, supra; Pursel et al, Science (1989) 244:1281-1288; Simms et al, Bio/Technology (1988) 6:179-183).
  • knock-out animals such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH et al., (1994) Scan J Immunol 40:257-264; DeclerckPJ et al., (1995) J Biol Chem. 270:8397-400).
  • the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MP2153 gene, e.g., by introduction of additional copies of MP2153, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MP2153 gene.
  • a regulatory sequence include inducible, tissue-specific, and constitutive promoters and enhancer elements.
  • the knock-in can be homozygous or heterozygous.
  • Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene.
  • a system that may be produced is the cre/loxP recombinase system of bacteriophage PI (Lakso et al, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required.
  • Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O 'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182).
  • both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).
  • the genetically modified animals can be used in genetic studies to further elucidate the p21 or p53 pathway, as animal models of disease and disorders implicating defective p21 or p53 function, and for in vivo testing of candidate therapeutic agents, such as those identified in screens described below.
  • the candidate therapeutic agents are administered to a genetically modified animal having altered MP2153 function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MP2153 expression that receive candidate therapeutic agent.
  • animal models having defective p21 or p53 function can be used in the methods of the present invention.
  • a p21 or p53 knockout mouse can be used to assess, in vivo, the activity of a candidate p21 or p53 modulating agent identified in one of the in vitro assays described below.
  • p53 knockout mice are described in the literature (Jacks et al., Nature 2001;410:1111-1116, 1043-1044; Donehower et al, supra), and p21 knockout mice are also described in the literature (Umanoff H, et al., Proc Natl Acad Sci U S A 1995 Feb 28;92(5): 1709-13).
  • the candidate p21 or p53 modulating agent when administered to a model system with cells defective in p21 or p53 function, produces a detectable phenotypic change in the model system indicating that the p21 or p53 function is restored, i.e., the cells exhibit normal cell cycle progression.
  • the invention provides methods to identify agents that interact with and/or modulate the function of MP2153 and/or the p21 or p53 pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the p21 or p53 pathway, as well as in further analysis of the MP2153 protein and its contribution to the p21 or p53 pathway. Accordingly, the invention also provides methods for modulating the p21 or p53 pathway comprising the step of specifically modulating MP2153 activity by administering a MP2153-interacting or -modulating agent. As used herein, an "MP2153-modulating agent" is any agent that modulates
  • MP2153 function for example, an agent that interacts with MP2153 to inhibit or enhance MP2153 activity or otherwise affect normal MP2153 function.
  • MP2153 function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity.
  • the MP2153 - modulating agent specifically modulates the function of the MP2153.
  • the phrases "specific modulating agent”, “specifically modulates”, etc., are used herein to refer to modulating agents that directly bind to the MP2153 polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MP2153. These phrases also encompass modulating agents that alter the interaction of the MP2153 with a binding partner, substrate, or cof actor (e.g.
  • the MP2153-modulating agent is a modulator of the p21 or p53 pathway (e.g. it restores and/or upregulates p21 or p53 function) and thus is also a p21 or p53- modulating agent.
  • Preferred MP2153-modulating agents include small molecule compounds;
  • MP2153-interacting proteins including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors.
  • the modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences” Mack Publishing Co., Easton, PA, 19 th edition. Small molecule modulators
  • Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains.
  • Chemical agents referred to in the art as "small molecule” compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500 daltons.
  • This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MP2153 protein or may be identified by screening compound libraries.
  • modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MP2153-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).
  • Small molecule modulators identified from screening assays can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the p21 or p53 pathway.
  • the activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing.
  • candidate clinical compounds are generated with specific regard to clinical and pharmacological properties.
  • the reagents may be derivatized and re-screened using in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development.
  • MP2153-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the p21 or p53 pathway and related disorders, as well as in validation assays for other MP2153 -modulating agents.
  • MP2153 -interacting proteins affect normal MP2153 function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity.
  • MP2153-interacting proteins are useful in detecting and providing information about the function of MP2153 proteins, as is relevant to p21 or p53 related disorders, such as cancer (e.g., for diagnostic means).
  • An MP2153-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MP2153, such as a member of the MP2153 pathway that modulates MP2153 expression, localization, and or activity.
  • MP2153-modulators include dominant negative forms of MP2153-interacting proteins and of MP2153 proteins themselves.
  • Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MP2153-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning- Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp.
  • Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3 rd , Trends Genet (2000) 16:5-8).
  • An MP2153-interacting protein may be an exogenous protein, such as an MP2153-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MP2153 antibodies are further discussed below. In preferred embodiments, an MP2153-interacting protein specifically binds an MP2153-specific antibody.
  • an MP2153-modulating agent binds an MP2153 substrate, binding partner, or cof actor.
  • the protein modulator is an MP2153 specific antibody agonist or antagonist.
  • the antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MP2153 modulators.
  • the antibodies can also be used in dissecting the portions of the MP2153 pathway responsible for various cellular responses and in the general processing and maturation of the MP2153.
  • Antibodies that specifically bind MP2153 polypeptides can be generated using known methods.
  • the antibody is specific to a mammalian ortholog of MP2153 polypeptide, and more preferably, to human MP2153.
  • Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti- idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • Epitopes of MP2153 which are particularly antigenic can be selected, for example, by routine screening of MP2153 polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol.
  • MP2153 fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MP2153 protein.
  • MP2153-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response.
  • the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response.
  • KLH keyhole limpet hemocyanin
  • An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.
  • MP2153-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MP2153 polypeptides.
  • an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MP2153 polypeptides.
  • ELISA enzyme-linked immunosorbant assay
  • Other assays such as radioimmunoassays or fluorescent assays might also be used.
  • Chimeric antibodies specific to MP2153 polypeptides can be made that contain different portions from different animal species.
  • a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment.
  • Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al, Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454).
  • Humanized antibodies which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain -10% murine sequences and -90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).
  • MP2153-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).
  • T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, supra).
  • polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., it J. Biol Markers (1989) 4: 131-134).
  • labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350;
  • the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously.
  • the therapeutically effective dose and dosage regimen is determined by clinical studies.
  • the amount of antibody administered is in the range of about 0.1 mg/kg -to about 10 mg/kg of patient weight.
  • the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle.
  • a pharmaceutically acceptable vehicle e.g., water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used.
  • the vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential.
  • the antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to aboutlO mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).
  • MP2153-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MP2153 activity.
  • Preferred nucleic acid modulators interfere with the function of the dsRNA
  • the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MP2153 mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region.
  • MP2153-specific antisense oligonucleotides preferably range from at least 6 to about 200 nucleotides.
  • the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length.
  • the oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded.
  • the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone.
  • the oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.
  • the antisense oligomer is a phosphothioate morpholino oligomer (PMO).
  • PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7: 187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).
  • RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene.
  • dsRNA double-stranded RNA
  • Methods relating to the use of RNAi to silence genes in C. elegans, Drosophila, plants, and humans are known in the art (Fire A, et al, 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S.
  • Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with extraordinar specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem.
  • an MP2153-specific nucleic acid modulator is used in an assay to further elucidate the role of the MP2153 in the p21 or p53 pathway, and/or its relationship to other members of the pathway.
  • an MP2153-specific antisense oligomer is used as a therapeutic agent for treatment of p21 or p53-related disease states.
  • an "assay system” encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event.
  • primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MP2153 nucleic acid or protein.
  • secondary assays further assess the activity of a MP2153 modulating agent identified by a primary assay and may confirm that the modulating agent affects MP2153 in a manner relevant to the p21 or p53 pathway. In some cases, MP2153 modulators will be directly tested in a secondary assay.
  • the screening method comprises contacting a suitable assay system comprising an MP2153 polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects.
  • a reference activity e.g. binding activity
  • a statistically significant difference between the agent- biased activity and the reference activity indicates that the candidate agent modulates MP2153 activity, and hence the p21 or p53 pathway.
  • the MP2153 polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.
  • the type of modulator tested generally determines the type of primary assay.
  • screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS et al, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references).
  • cell-based refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction.
  • cell free encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts.
  • Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicty and changes in cellular morphology or other cellular characteristics.
  • Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.
  • Cell-based screening assays usually require systems for recombinant expression of MP2153 and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MP2153-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MP2153 protein may be assayed by various known methods such as substrate processing (e.g.
  • binding equilibrium constants usually at least about 10 7 M "1 , preferably at least about 10 8 M "1 , more preferably at least about 10 9 M "1
  • immunogenicity e.g. ability to elicit MP2153 specific antibody in a heterologous host such as a mouse, rat, goat or rabbit.
  • binding may be assayed by, respectively, substrate and ligand processing.
  • the screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MP2153 polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein.
  • the MP2153 polypeptide can be full length or a fragment thereof that retains functional MP2153 activity.
  • the MP2153 polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag.
  • the MP2153 polypeptide is preferably human MP2153, or is an ortholog or derivative thereof as described above.
  • the screening assay detects candidate agent-based modulation of MP2153 interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MP2153 -specific binding activity, and can be used to assess normal MP2153 gene function.
  • a binding target such as an endogenous or exogenous protein or other substrate that has MP2153 -specific binding activity
  • screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53).
  • screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer.
  • Transporter proteins carry a range of substrates, including nutrients, ions, amino acids, and drugs, across cell membranes. Assays for modulators of transporters may use labeled substrates.
  • exemplary high throughput screens to identify compounds that interact with different peptide and anion transporters both use fluorescently labeled substrates; the assay for peptide transport additionally uses multiscreen filtration plates (Blevitt JM et al, J Biomol Screen 1999, 4: 87-91 ; Cihlar T and Ho ES, Anal Biochem 2000, 283:49-55).
  • the screening assay detects the ability of the test agent to modulate the kinase activity of an MP2153 polypeptide.
  • a cell-free kinase assay system is used to identify a candidate p21 or p53 modulating agent, and a secondary, cell-based assay, such as an apoptosis or hypoxic induction assay (described below), may be used to further characterize the candidate p21 or p53 modulating agent.
  • a secondary, cell-based assay such as an apoptosis or hypoxic induction assay (described below)
  • Radioassays which monitor the transfer of a gamma phosphate are frequently used.
  • a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from gamma - P ATP to a biotinylated peptide substrate; the substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M et al, J Biomol Screen (2000) 5:205-212).
  • This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from free ligand.
  • Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates.
  • the kinase receptor activation (KIRA) assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133).
  • TRF time- resolved fluorometry
  • This method utilizes europium chelate-labeled anti- phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time- resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2): 159-64).
  • Apoptosis assays may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay.
  • TUNEL terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling
  • the TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis ( Lazebnik et al, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara et al, 1989, J. Exp. Med. 169, 1747).
  • Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41).
  • cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay.
  • the caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways.
  • the caspase 3/7 assay commercially available Apo- ONETM Homogeneous Caspase-3/7 assay from Promega, cat# 67790
  • lysis buffer and caspase substrate are mixed and added to cells.
  • the caspase substrate becomes fluorescent when cleaved by active caspase 3/7.
  • the nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumalation in the cytoplasm.
  • Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis.
  • An apoptosis assay system may comprise a cell that expresses an MP2153, and that optionally has defective p21 or p53 function (e.g. p21 or p53 is over expressed or under-expressed relative to wild- type cells).
  • a test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate p21 or p53 modulating agents.
  • an apoptosis assay may be used as a secondary assay to test a candidate p21 or p53 modulating agents that is initially identified using a cell-free assay system.
  • An apoptosis assay may also be used to test whether MP2153 function plays a direct role in apoptosis.
  • an apoptosis assay may be performed on cells that over- or under-express MP2153 relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MP2153 plays a direct role in the apoptotic response.
  • Apoptosis assays are described further in US Pat. No. 6,133,437.
  • Cell proliferation and cell cycle assays may be assayed via bromodeoxyuridine (BRDU) incorporation.
  • BRDU bromodeoxyuridine
  • Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino et al., 1986, Int. J. Cancer 38, 369; Campana et al., 1988, J. Immunol. Meth. 107, 79), or by other means.
  • an anti-BRDU antibody Hoshino et al., 1986, Int. J. Cancer 38, 369; Campana et al., 1988, J. Immunol. Meth. 107, 79
  • Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specfic to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098- 105). Cell Proliferation may also be examined using [ 3 H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73).
  • This assay allows for quantitative characterization of S-phase DNA syntheses.
  • cells synthesizing DNA will incorporate [ 3 H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter).
  • a scintillation counter e.g., Beckman LS 3800 Liquid Scintillation Counter.
  • Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Noytik-Harbin SL et al., 1998, In Nitro Cell Dev Biol Anim 34:239-46).
  • MTS assay is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS.
  • MTS assays are commercially available, for example, the Promega CellTiter 96 ® AQueous ⁇ on-Radioactive Cell Proliferation Assay (Cat.# G5421).
  • Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with MP2153 are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.
  • Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells.
  • assays are commercially available, for example Cell Titer-GloTM, which is a luminescent homogeneous assay available from Promega.
  • Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55).
  • Cells transfected with an MP2153 may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.
  • a cell proliferation or cell cycle assay system may comprise a cell that expresses an MP2153, and that optionally has defective p21 or p53 function (e.g. p21 or p53 is over-expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate p21 or p53 modulating agents.
  • the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate p21 or p53 modulating agents that is initially identified using another assay system such as a cell-free assay system.
  • a cell proliferation assay may also be used to test whether MP2153 function plays a direct role in cell proliferation or cell cycle.
  • a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MP2153 relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggest that the MP2153 plays a direct role in cell proliferation or cell cycle.
  • Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson).
  • Alamar Blue based assays available from Biosource International
  • migration assays using fluorescent molecules such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors
  • tubule formation assays based on the formation of tubular structures by endothelial cells on Ma
  • an angiogenesis assay system may comprise a cell that expresses an MP2153, and that optionally has defective p21 or p53 function (e.g. p21 or p53 is over-expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate p21 or p53 modulating agents.
  • the angiogenesis assay may be used as a secondary assay to test a candidate p21 or p53 modulating agents that is initially identified using another assay system.
  • An angiogenesis assay may also be used to test whether MP2153 function plays a direct role in cell proliferation.
  • an angiogenesis assay may be performed on cells that over- or under-express MP2153 relative to wild type cells. Differences in angiogenesis compared to wild type cells suggest that the MP2153 plays a direct role in angiogenesis.
  • hypoxia inducible factor- 1 The alpha subunit of the transcription factor, hypoxia inducible factor- 1 (HJF-1), is upregulated in tumor cells following exposure to hypoxia in vitro.
  • EHF-l stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF.
  • Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MP2153 in hypoxic conditions (such as with 0.1% O2, 5% CO2, and balance N2, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®.
  • a hypoxic induction assay system may comprise a cell that expresses an MP2153, and that optionally has defective p21 or p53 function (e.g. p21 or p53 is over- expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate p21 or p53 modulating agents.
  • the hypoxic induction assay may be used as a secondary assay to test a candidate p21 or p53 modulating agents that is initially identified using another assay system.
  • a hypoxic induction assay may also be used to test whether MP2153 function plays a direct role in the hypoxic response.
  • a hypoxic induction assay may be performed on cells that over- or under-express MP2153 relative to wild type cells. Differences in hypoxic response compared to wild type cells suggest that the MP2153 plays a direct role in hypoxic induction.
  • Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents.
  • Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2x final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.
  • a membrane-permeable fluorescent dye such as calcein-AM
  • Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice.
  • cells expressing the cell adhesion protein are plated in wells of a multiwell plate.
  • Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.
  • High-throughput cell adhesion assays have also been described.
  • small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off.
  • this assay not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53). Tubulogenesis.
  • Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix.
  • exemplary substrates include MatrigelTM (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen JN, and heparin sulfate proteoglycan, which is liquid at 4° C and forms a solid gel at 37° C.
  • Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging.
  • Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used.
  • Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors.
  • the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates.
  • different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF-alpa.
  • a tubulogenesis assay system comprises testing an MP2153's response to a variety of factors, such as FGF, VEGF, phorbol rnyristate acetate (PMA), TNF-alpha, ephrin, etc.
  • factors such as FGF, VEGF, phorbol rnyristate acetate (PMA), TNF-alpha, ephrin, etc.
  • An invasion/migration assay tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals.
  • Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837).
  • cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size.
  • the matrix generally simulates the environment of the extracellular matrix, as described above.
  • the lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson).
  • a preferred assay system for migration/invasion assays comprises testing an MP2153's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.
  • a sprouting assay is a three-dimensional in vitro angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix.
  • the spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58).
  • spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 ⁇ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 ⁇ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.
  • ELISA enzyme-linked immunosorbant assay
  • screening assays described for small molecule modulators may also be used to test antibody modulators.
  • Primary assays for nucleic acid modulators may also be used to test antibody modulators.
  • primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MP2153 gene expression, preferably mRNA expression.
  • expression analysis comprises comparing MP2153 expression in like populations of cells (e.g., two pools of cells that endogenously or recombinantly express MP2153) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art.
  • Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MP2153 protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, supra).
  • screening assays described for small molecule modulators may also be used to test nucleic acid modulators.
  • Secondary assays may be used to further assess the activity of MP2153-modulating agent identified by any of the above methods to confirm that the modulating agent affects MP2153 in a manner relevant to the p21 or p53 pathway.
  • MP2153- modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent.
  • Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MP2153.
  • Secondary assays generally compare like populations of cells or animals (e.g., two pools of cells or animals that endogenously or recombinantly express MP2153) in the presence and absence of the candidate modulator.
  • such assays test whether treatment of cells or animals with a candidate MP2153-modulating agent results in changes in the p21 or p53 pathway in comparison to untreated (or mock- or placebo- treated) cells or animals.
  • Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the p21 or p53 or interacting pathways.
  • Cell based assays may use a variety of mammalian cell lines known to have defective p21 or p53 function (e.g. SAOS-2 osteoblasts, H1299 lung cancer cells, C33A and HT3 cervical cancer cells, HT-29, HCT116, andDLD-1 colon cancer cells, among others, available from American Type Culture Collection (ATCC), Manassas, VA).
  • Cell based assays may detect endogenous p21 or p53 pathway activity or may rely on recombinant expression of p21 or p53 pathway components. Any of the aforementioned assays may be used in this cell-based format.
  • Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.
  • Models for defective p21 or p53 pathway typically use genetically modified animals that have been engineered to mis- express (e.g., over-express or lack expression in) genes involved in the p21 or p53 pathway.
  • Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.
  • p21 or p53 pathway activity is assessed by monitoring neovascularization and angiogenesis.
  • Animal models with defective and normal p21 or p53 are used to test the candidate modulator's affect on MP2153 in Matrigel® assays.
  • Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen JN, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over- express the MP2153.
  • mice Female athymic nude mice (Taconic, Germantown, ⁇ Y) to support an intense vascular response.
  • Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (JP), or intravenous (JN) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.
  • the effect of the candidate modulator on MP2153 is assessed via tumorigenicity assays.
  • Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from in vitro culture. The tumors which express the MP2153 endogenously are injected in the flank, 1 x 10 5 to 1 x 10 7 cells per mouse in a volume of 100 ⁇ L using a 27 gauge needle. Mice are then ear tagged and tumors are measured twice weekly.
  • Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg.
  • Candidate modulator is delivered TN, SC, JP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day.
  • the tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions.
  • the excised tumors maybe utilized for biomarker identification or further analyses.
  • xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.
  • tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413.
  • the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator.
  • Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line.
  • Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.
  • a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays.
  • tumor development in the transgenic model is well characterized or is controlled.
  • the "RTP1-Tag2" transgene comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315: 115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812).
  • the RIP1-TAG2 mice die by age 14 weeks.
  • Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression).
  • Tumorogenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.
  • MP2153-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the p21 or p53 pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the p21 or ⁇ 53 pathway in a cell, preferably a cell pre-determined to have defective or impaired p21 or p53 function (e.g. due to overexpression, underexpression, or misexpression of p21 or p53, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MP2153 activity.
  • a cell pre-determined to have defective or impaired p21 or p53 function e.g. due to overexpression, underexpression, or misexpression of p21 or p53, or due to gene mutations
  • the modulating agent produces a detectable phenotypic change in the cell indicating that the p21 or p53 function is restored.
  • function is restored means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells.
  • cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells.
  • the invention also provides methods for treating disorders or disease associated with impaired p21 or p53 function by administering a therapeutically effective amount of an MP2153 - modulating agent that modulates the p21 or p53 pathway.
  • the invention further provides methods for modulating MP2153 function in a cell, preferably a cell pre-determined to have defective or impaired MP2153 function, by administering an MP2153 -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MP2153 function by administering a therapeutically effective amount of an MP2153 -modulating agent.
  • MP2153 is implicated in p21 or p53 pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the p21 or p53 pathway and for the identification of subjects having a predisposition to such diseases and disorders.
  • Various expression analysis methods can be used to diagnose whether MP2153 expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis, (e.g., Current
  • Tissues having a disease or disorder implicating defective p21 or p53 signaling that express an MP2153 are identified as amenable to treatment with an MP2153 modulating agent.
  • the p21 or p53 defective tissue overexpresses an MP2153 relative to normal tissue.
  • a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MP2153 cDNA sequences as probes, can determine whether particular tumors express or overexpress MP2153.
  • the TaqMan® is used for quantitative RT-PCR analysis of MP2153 expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).
  • reagents such as the MP2153 oligonucleotides, and antibodies directed against an MP2153, as described above for: (1) the detection of the presence of MP2153 gene mutations, or the detection of either over- or under-expression of MP2153 mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MP2153 gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MP2153.
  • the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MP2153 expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MP2153 expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder.
  • the disease is cancer.
  • the probe may be either DNA or protein, including an antibody.
  • Drosophila p21 screen A dominant loss of function screen was carried out in Drosophila to identify genes that interact with the cyclin dependent kinase inhibitor, p21 (Bourne HR, et al., Nature (1990) 348(6297): 125-132; Marshall CJ, Trends Genet (1991) 7(3):91-95).
  • Expression of the p21 gene from GMR- ⁇ 21 transgene (Hay, B. A., et al. (1994) Developmentl20:2121- 2129) in the eye causes deterioration of normal eye morphology, resulting in reduced, rough eyes.
  • Flies carrying this transgene were maintained as a stock (P 1025 F, genotype: y w; P ⁇ p21-pExp-gl-w[+]Hsp70(3'UTR)-5 ⁇ ).
  • Females of this stock were crossed to a collection of males carrying piggyBac insertions (Fraser M et al, Virology (1985) 145:356-361).
  • Resulting progeny carrying both the transgene and transposons were scored for the effect of the transposon on the eye phenotype, i.e. whether the transposon enhanced or suppressed (or had no effect) the eye phenotype. All data was recorded and all modifiers were retested with a repeat of the original cross, and the retests were scored at least twice. Modifiers of the eye phenotype were identified as members of the p21 pathway.
  • Drosophila p53 screen The Drosophila p53 gene was overexpressed specifically in the wing using the vestigial margin quadrant enhancer. Increasing quantities of Drosophila p53 (titrated using different strength transgenic inserts in 1 or 2 copies) caused deterioration of normal wing morphology from mild to strong, with phenotypes including disruption of pattern and polarity of wing hairs, shortening and thickening of wing veins, progressive crumpling of the wing and appearance of dark "death" inclusions in wing blade.
  • MP2153s as available from National Center for Biology Information (NCBI), MP2153 protein Genbank identifier number (GI#), MP2153 name, and MP2153 description, all available from Genbank, respectively.
  • the length of each amino acid is in the "MP2153 Protein Length" column. Names and Protein sequences of Drosophila modifiers of p21 or p53 from screen
  • Example I are represented in the "Modifier Name” and “Modifier GI_AA” column by GI#, respectively.
  • Fluorescently-labeled MP2153 peptide/substrate are added to each well of a 96- well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM ⁇ aCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MP2153 activity.
  • the cell lysate is incubated with 25 ⁇ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking. After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).
  • ECL enhanced chemiluminescence
  • the enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by increasing assay throughput. A 96-well microtiter plate is employed using a final volume 30-100 ⁇ l. The reaction is initiated by the addition of 33 P-gamma-ATP (0.5 ⁇ Ci/ml) and incubated for 0.5 to 3 hours at room temperature.
  • Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg2 + or Mn 2+ ) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate
  • RNA is extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/ ⁇ l.
  • Single stranded cDNA is then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).
  • Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) are prepared according to the TaqMan protocols, and the following criteria: a) primer pairs are designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis is performed using a 7900HT instrument.
  • Taqman reactions are carried out following manufacturer's protocols, in 25 ⁇ l total volume for 96-well plates and 10 ⁇ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA.
  • the standard curve for result analysis is prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good.
  • the raw data are normalized using 18S rRNA (universally expressed in all tissues and cells).
  • tumor tissue samples are compared with matched normal tissues from the same patient.
  • a gene is considered overexpressed in a tumor when the level of expression of the gene is 2 fold or higher in the tumor compared with its matched normal sample.
  • a universal pool of cDNA samples is used instead.
  • a gene is considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type is greater than 2 times the standard deviation of all normal samples (i.e., Tumor - average(all normal samples) > 2 x STDEN(all normal samples) ).
  • a modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed.
  • a decrease in tumor growth confirms therapeutic utility of the modulator.
  • the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator.
  • the expression data for the gene(s) can also be used as a diagnostic marker for disease progression.
  • the assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des gènes humains MP2153 identifiés comme modulateurs de la voie de p21 ou de p53, qui constituent des cibles thérapeutiques pour traiter des troubles associés à une fonction déficiente de p21 ou de p53 ; et des procédés d'identification de modulateurs de p21 ou de p53, qui comprennent le criblage d'agents modulant l'activité de MP2153.
PCT/US2003/024505 2002-08-07 2003-08-06 Mp2153 comme genes modificateurs de la voie de p21 ou de p53 et procedes d'utilisation WO2004015069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263993A AU2003263993A1 (en) 2002-08-07 2003-08-06 MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40170102P 2002-08-07 2002-08-07
US60/401,701 2002-08-07
US41101702P 2002-09-16 2002-09-16
US60/411,017 2002-09-16
US43710702P 2002-12-30 2002-12-30
US60/437,107 2002-12-30

Publications (2)

Publication Number Publication Date
WO2004015069A2 true WO2004015069A2 (fr) 2004-02-19
WO2004015069A3 WO2004015069A3 (fr) 2004-09-02

Family

ID=31721494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024505 WO2004015069A2 (fr) 2002-08-07 2003-08-06 Mp2153 comme genes modificateurs de la voie de p21 ou de p53 et procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2003263993A1 (fr)
WO (1) WO2004015069A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014162962A1 (fr) * 2013-04-01 2014-10-09 学校法人 久留米大学 Peptide dérivé d'un antigène tumoral

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
US6071696A (en) * 1996-12-30 2000-06-06 The Trustees Of Columbia University In The City Of New York Method of producing a temporally spaced subtracted (TSS) CDNA library and use thereof to monitor differentiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
US6071696A (en) * 1996-12-30 2000-06-06 The Trustees Of Columbia University In The City Of New York Method of producing a temporally spaced subtracted (TSS) CDNA library and use thereof to monitor differentiation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANG ET AL: 'P21 Wafl/Cip1/Sdil induces permanent growth arrest with markers of replicative senescense in human tumor cells lacking functional p53' ONCOGENE vol. 18, 1999, pages 2789 - 2797, XP000922664 *
IRBY R.B. ET AL: 'Activating SRC mutation in a subset of advanced human colon cancers' NATURE GENETICS vol. 21, February 1999, pages 187 - 190, XP002978021 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014162962A1 (fr) * 2013-04-01 2014-10-09 学校法人 久留米大学 Peptide dérivé d'un antigène tumoral
JPWO2014162962A1 (ja) * 2013-04-01 2017-02-16 学校法人 久留米大学 腫瘍抗原ペプチド

Also Published As

Publication number Publication date
WO2004015069A3 (fr) 2004-09-02
AU2003263993A1 (en) 2004-02-25
AU2003263993A8 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2003083047A2 (fr) Genes mp53 en tant que modificateurs de la voie des proteines p53 et methodes d'utilisation
WO2004024880A2 (fr) Genes ampd modifiant le trajet p21, et procedes d'utilisation
WO2004004785A1 (fr) Agents mchk modificateurs de la voie metabolique de chk1 et procedes d'utilisation
WO2004048537A2 (fr) « lamps » modifiant la voie p53 et leurs procedes d'utilisation
WO2006009960A2 (fr) Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants
US20050251870A1 (en) Csnk1gs as modifiers of the p21 pathway and methods of use
WO2004005483A2 (fr) Adcy3s modificateurs de la voie p21 et methodes d'utilisation
WO2005017121A2 (fr) Mbcats modificateurs de la voie beta-catenine et methodes d'utilisation
WO2004005486A2 (fr) Genes mp21 utilises comme modificateurs de la voie p21 et leurs procedes d'utilisation
US20050266406A1 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004015072A2 (fr) Modificateurs de retinoblastomes (mrb) en tant que modificateurs de la voie des rb et methodes d'utilisation
WO2004065542A2 (fr) Mat2a utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2004015069A2 (fr) Mp2153 comme genes modificateurs de la voie de p21 ou de p53 et procedes d'utilisation
US20070286852A1 (en) Sppls as Modifiers of the P53 Pathway and Methods of Use
US20060063710A1 (en) Flj20647s as modifiers of the p21 pathway and methods of use
WO2004061123A2 (fr) Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation
WO2004048536A2 (fr) Rhebs utilises comme modificateurs de la voie rb et methodes d'utilisation
WO2004083389A2 (fr) Genes mbcat utilises comme modificateurs de la voie de la beta-catenine et techniques d'utilisation
WO2003074673A2 (fr) Lgals tenant lieu de modificateurs de la voie de chk et leurs procedes d'utilisation
EP1546704A2 (fr) Pak utilise en tant que modificateur de la voie de chk et procedes d'utilisation associes
WO2004004766A1 (fr) Agents mp53 modificateurs de la voie metabolique de p53 et procedes d'utilisation
WO2004104168A2 (fr) Mrb utilises comme modificateurs de la voie des rb et procedes d'utilisation correspondants
WO2005052579A1 (fr) Genes knsl en tant que modificateurs des voies apc et axin et leurs procedes d'utilisation
WO2005073724A1 (fr) Mbcats utiles comme genes modificateurs du mecanisme d'action de la beta-catenine et leurs methodes d'utilisation
WO2004024881A2 (fr) Ldlr utilise en tant que modificateur de la voie p53 et procedes d'utilisation associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP